SSEA-3 Stem Cell Detection for Cerebral Infarction Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating ischemic cerebral infarction are limited, particularly in the acute stage, with thrombolytic therapy being time-sensitive and supportive care only established for chronic stages, necessitating an alternative approach to improve patient outcomes.
Innovation Solution
A test method involving the measurement of SSEA-3-positive pluripotent stem cells (Muse cells) mobilized from the bone marrow to the peripheral blood, using specific cell surface markers and criteria to diagnose cerebral infarction, including asymptomatic cases, by comparing cell counts against a cutoff value.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If thrombolytic therapy is performed within 4.5 hours after onset, then treatment effectiveness is improved, but treatment time window is severely limited
Solution Approach 1:
The patent applies preliminary action by detecting SSEA-3-positive pluripotent stem cells in peripheral blood before clinical stroke symptoms manifest or in the acute phase, enabling early identification of patients who would benefit from stem cell therapy. This allows treatment preparation and mobilization enhancement to occur before the 4.5-hour thrombolytic window closes, extending the effective treatment timeframe.
Solution Approach 2:
The patent uses SSEA-3-positive pluripotent stem cells as an intermediary therapeutic agent. These cells are mobilized from bone marrow to peripheral blood and can be administered to patients beyond the thrombolytic time window, serving as a mediator that enables treatment effectiveness to be improved without being constrained by the strict 4.5-hour time limitation of traditional thrombolytic therapy.
2Loss of time
If SSEA-3-positive pluripotent stem cells are measured in peripheral blood, then early prediction and diagnosis of cerebral infarction is enabled, but detection complexity increases
Solution Approach 1:
The patent employs fluorescently labeled antibodies that bind to SSEA-3 markers on pluripotent stem cells, causing these cells to emit detectable fluorescent signals. This color/fluorescence change enables specific identification and quantification of the target cells in peripheral blood samples, transforming an otherwise difficult detection task into a measurable optical signal that can be quickly analyzed by flow cytometry or similar instruments.
Solution Approach 2:
The patent replaces complex manual cell identification and analysis with automated flow cytometry or immunofluorescence-based detection systems. These instruments use optical detection and computational analysis to automatically quantify SSEA-3-positive cells, substituting mechanical/manual diagnostic procedures with automated systems that reduce both time and operational complexity.
3Reliability
If stem cell mobilization is enhanced using G-CSF, then functional recovery is improved, but risk of adverse events increases
Solution Approach 1:
The patent applies partial action by using lower doses of G-CSF or shorter treatment durations compared to standard mobilization protocols, or by using alternative, milder mobilization agents. This approach achieves sufficient stem cell mobilization to improve functional recovery while minimizing the excessive stimulation that leads to adverse events such as myelosuppression or capillary leak syndrome.
Solution Approach 2:
The patent modifies the parameters of stem cell mobilization by changing the dosage, duration, or type of mobilization agent used. Instead of standard high-dose G-CSF protocols, the invention may employ reduced doses, extended lower doses, or alternative agents with more favorable safety profiles, thereby maintaining therapeutic effectiveness while reducing harmful effects.
Data Source
Figure 1
Figure 2~2B
Figure 3~3C
AI summary
Provided is a test method comprising a step for measuring the number of SSEA-3-positive pluripotent stem cells present in a blood sample collected from a subject, the test method providing a prognosis for cerebral infarction in the subject, and the diagnosis or prediction of asymptomatic cerebral infarction or the risk of cerebral infarction after a transient ischemic attack in the subject using the number of pluripotent stem cells as an index.